It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The use of pesticides to reduce mosquito vector populations is a cornerstone of global malaria control efforts, but the biological impact of most pesticides on human populations, including pregnant women and infants, is not known. Some pesticides, including carbamates, have been shown to perturb the human immune system. We measure the systemic absorption and immunologic effects of bendiocarb, a commonly used carbamate pesticide, following household spraying in a cohort of pregnant Ugandan women and their infants. We find that bendiocarb is present at high levels in maternal, umbilical cord, and infant plasma of individuals exposed during pregnancy, indicating that it is systemically absorbed and trans-placentally transferred to the fetus. Moreover, bendiocarb exposure is associated with numerous changes in fetal immune cell homeostasis and function, including a dose-dependent decrease in regulatory CD4 T cells, increased cytokine production, and inhibition of antigen-driven proliferation. Additionally, prenatal bendiocarb exposure is associated with higher post-vaccination measles titers at one year of age, suggesting that its impact on functional immunity may persist for many months after birth. These data indicate that in utero bendiocarb exposure has multiple previously unrecognized biological effects on the fetal immune system.
Control of mosquito populations using pesticides is important for malaria elimination, but effects of pesticides on humans aren’t well understood. Here, Prahl et al. show in a cohort of pregnant Ugandan women and their infants that household spraying with bendiocarb affects the fetal immune system and response to vaccination in infancy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 University of California San Francisco, Department of Pediatrics, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
2 University of California San Francisco, Department of Medicine, Zuckerberg San Francisco General Hospital, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
3 University of California San Francisco, Drug Research Unit, Department of Clinical Pharmacy, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
4 Infectious Diseases Research Collaboration, Kampala, Uganda (GRID:grid.463352.5)
5 Stanford University, Department of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
6 Infectious Diseases Research Collaboration, Kampala, Uganda (GRID:grid.463352.5); Makerere University, Department of Medicine, Kampala, Uganda (GRID:grid.11194.3c) (ISNI:0000 0004 0620 0548)
7 University of California San Francisco, Department of Pediatrics, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California San Francisco, Department of Medicine, Zuckerberg San Francisco General Hospital, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)